Notification That Annual Report Will Be Submitted Late (nt 10-k)
March 30 2020 - 3:25PM
Edgar (US Regulatory)
|
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
|
|
|
|
|
|
|
|
|
|
|
|
FORM
12b-25
|
SEC FILE NUMBER
|
|
0-28666
|
|
|
|
|
|
|
|
CUSIP NUMBER
|
|
NOTIFICATION
OF LATE FILING
|
024600
|
(Check one):
|
☑
|
Form
10-K
|
☐
|
Form
20-F
|
☐
|
Form
11-K
|
☐
|
Form
10-Q
|
☐
|
Form
10-D
|
☐
|
Form
N-SAR
|
☐
|
Form
N-CSR
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For Period Ended:
December
31, 2019
|
|
|
|
|
|
|
|
|
|
|
☐
|
Transition
Report on Form 10-K
|
|
|
|
|
|
|
☐
|
Transition
Report on Form 20-F
|
|
|
|
|
|
|
☐
|
Transition
Report on Form 11-K
|
|
|
|
|
|
|
☐
|
Transition
Report on Form 10-Q
|
|
|
|
|
|
|
☐
|
Transition
Report on Form N-SAR
|
|
|
|
|
|
|
|
|
For the Transition
Period Ended:
|
Nothing in this form shall be construed to imply that the
Commission has verified any information contained
herein.
If the
notification relates to a portion of the filing checked above,
identify the Item(s) to which the notification
relates: Not
Applicable
PART I - REGISTRANT INFORMATION
American Bio Medica Corporation
Full
name of registrant
Former
Name if Applicable
Address
of Pincipal Eecutive Ofice (Sreet and Number)
Kinderhook, New York
12106
City,
Sate and Zip Code
PART II - RULES 12b-25(b) AND (c)
If the
subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25(b),
the following should be completed. (Check box if
appropriate)
|
(a)
|
The reason
described in reasonable detail in Part III of this form could not
be eliminated without unreasonable effort or expense
|
|
|
|
☒
|
(b)
|
The subject annual
report, semi-annual report, transition report on Form 10-K, Form
20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will
be filed on or before the fifteenth calendar day following the
prescribed due date; or the subject quarterly report or transition
report on Form 10-Q or subject distribution report on Form 10-D, or
portion thereof, will be filed on or before the fifth calendar day
following the prescribed due date; and
|
|
|
|
|
(c)
|
The
accountant’s statement or other exhibit required by Rule
12b-25(c) has been attached if applicable.
|
|
|
|
PART III - NARRATIVE
State
below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K,
10-Q, 10-D, N-SAR, N-CSR or the transition report or portion
thereof, could not be filed within the prescribed time period.
(Attach extra Sheets if Needed.)
The registrant is not able to timely file its requisite annual
report on Form 10-K for the fiscal year ended December 31, 2019 by
the prescribed due date without incurring undue hardship and
expense. The registrant, its consultants and advisors are being
impacted by government imposed restrictions due to the outbreak of
corornavirus (COVID-19), which has contributed to the delay in
compiling and completing the registrant’s annual report. The
registrant reasonably believes that it will be able to complete and
file its Form 10-K for December 31, 2019 within the prescribed,
extended extension period, on or prior to May 14,
2020.
PART IV - OTHER INFORMATION
(1)
|
Name and telephone
number of person to contact in regard to this
notification
|
|
|
Melissa
A. Waterhouse
|
|
(518)
|
|
758-8158
|
|
(Name)
|
|
(Area
Code)
|
|
(Telephone
Number)
|
|
(2)
|
Have all other
periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such
shorter period that the registrant was required to file such
report(s) been filed? If answer is no, identify
report(s).
|
Yes
|
☒
|
No
|
☐
|
|
|
|
|
(3)
|
Is it anticipated
that any significant change in results of operations from the
corresponding period for the last fiscal year will be reflected by
the earnings statements to be included in the subject report or
portion thereof?
|
Yes
|
☐
|
No
|
☒
|
|
|
|
If so, attach an
explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a
reasonable estimate of the results cannot be made.
|
AMERICAN BIO MEDICA CORPORATION
(Name
of Registrant as Specified in Charter)
Has
caused this notification to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
|
By:
|
/s/ Melissa A.
Waterhouse
|
|
|
|
|
Melissa A.
Waterhouse
|
|
|
|
|
Chief Executive
Officer / Pricipal Financial Officer
|
American Bio Medica (CE) (USOTC:ABMC)
Historical Stock Chart
From Aug 2024 to Sep 2024
American Bio Medica (CE) (USOTC:ABMC)
Historical Stock Chart
From Sep 2023 to Sep 2024